Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASER: Lurbinectedin With or Without Avelumab in SCCB and HGNET
NCT06228066Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in small cell carcinoma of the bladder (SCCB), neuroendocrine tumor of the urinary tract (UT-NET), sponsored by National Cancer Institute. Started Jun 2024; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell carcinoma of the bladder (SCCB)neuroendocrine tumor of the urinary tract (UT-NET)
Beyond the preview
Go deeper on NCT06228066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06228066.